Please assess the completion status of the following clinical trial:

Trial Title: Add-on to Micamlo BP Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Essential hypertensive patients who have already taking 2 or 3 antihypertensive drugs and mean seated diastolic blood pressure (DBP) must be \>=90 and \<=114 mmHg and mean seated systolic blood pressure (SBP) must be =\<200 mmHg~* Able to stop all current antihypertensive drugs (other than study medication) from Visit 1b through the end of the trial without risk to the patient based on the investigator's opinion~* Age 20 years or older~Exclusion criteria:~* Patients with known or suspected secondary hypertension~* Patients with clinically relevant cardiac arrhythmia~* Congestive heart failure with New York Heart Association (NYHA) functional class III-IV~* Patients with recent cardiovascular events~* Patients with recent stroke events~* Patients with a history of sudden deterioration of renal function with angiotensin II receptor blockers or angiotensin converting enzyme inhibitors; or patients with post-renal transplant or post-nephrectomy~* Patients with hepatic and/or renal dysfunction~* Pre-menopausal women who are nursing or pregnant

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Telmisartan+amlodipine+HCTZ (Type: EXPERIMENTAL): telmisartan 80 mg + amlodipine 5 mg fixed dose combination (FDC) and hydrochlorothiazide (HCTZ) 12.5 mg tablet
- Telmisartan+amlodipine (Type: ACTIVE_COMPARATOR): telmisartan 80 mg + amlodipine 5 mg fixed dose combination (FDC) and placebo matching hydrochlorothiazide 12.5 mg tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).